164 related articles for article (PubMed ID: 34721029)
1. Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China.
Li Z; Liu C; Zuo K; Liu J; Tang Y
Front Pharmacol; 2021; 12():741671. PubMed ID: 34721029
[No Abstract] [Full Text] [Related]
2. Pricing of HPV tests in Italian tender-based settings.
Inturrisi F; Berkhof J
J Med Econ; 2022; 25(1):762-768. PubMed ID: 35616231
[TBL] [Abstract][Full Text] [Related]
3. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
Long H; Yang Y; Geng X; Mao Z; Mao Z
Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
[No Abstract] [Full Text] [Related]
4. Delivery of Essential Medicines to Primary Care Institutions and its Association with Procurement Volume and Price: A Case Study in Hubei Province, China.
Tang Y; Liu C; Zhang X
Appl Health Econ Health Policy; 2017 Feb; 15(1):57-64. PubMed ID: 27613726
[TBL] [Abstract][Full Text] [Related]
5. How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014.
Hamzah NM; Perera PN; Rannan-Eliya RP
BMC Health Serv Res; 2020 Jun; 20(1):509. PubMed ID: 32503539
[TBL] [Abstract][Full Text] [Related]
6. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
[TBL] [Abstract][Full Text] [Related]
7. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
8. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China.
Yang H; Dib HH; Zhu M; Qi G; Zhang X
Health Policy Plan; 2010 May; 25(3):219-29. PubMed ID: 19955093
[TBL] [Abstract][Full Text] [Related]
9. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
Zhu Y; Wang Y; Sun X; Li X
Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
[TBL] [Abstract][Full Text] [Related]
10. Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China.
Tang Y; Liu C; Liu J; Zhang X; Zuo K
Pharmacoeconomics; 2018 Aug; 36(8):995-1004. PubMed ID: 29671132
[TBL] [Abstract][Full Text] [Related]
11. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
Rong X; Yin J; Duan S; Sun Q; Babar ZU
BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
13. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
14. Association between provincial income levels and drug prices in China over the period 2010-2017.
Shi W; Wouters OJ; Liu G; Mossialos E; Yang X
Soc Sci Med; 2020 Oct; 263():113247. PubMed ID: 32799026
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia's Social Health Insurance System.
Anggriani Y; Ramadaniati HU; Sarnianto P; Pontoan J; Suryawati S
Value Health Reg Issues; 2020 May; 21():1-8. PubMed ID: 31634791
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Price and Availability of Essential Medicines in China: A Mixed Cross-Sectional and Longitudinal Study.
Yang C; Hu S; Ye D; Jiang M; Babar ZU; Fang Y
Front Pharmacol; 2020; 11():602421. PubMed ID: 33381042
[No Abstract] [Full Text] [Related]
17. The Effects of a New Public Medicine Procurement Policy on Medicine Price in Shaanxi Province, Western China: An Interrupted Time Series Analysis.
Hu S; Chen C; Yuan S; Xue F; Shi L; Fang Y; Yang C
Front Pharmacol; 2019; 10():950. PubMed ID: 31555135
[No Abstract] [Full Text] [Related]
18. Does managed competition constrain hospitals' contract prices? Evidence from the Netherlands.
Douven R; Burger M; Schut F
Health Econ Policy Law; 2020 Jul; 15(3):341-354. PubMed ID: 30973119
[TBL] [Abstract][Full Text] [Related]
19. Improving access to medicines and beyond: the national volume-based procurement policy in China.
Zhu Z; Wang Q; Sun Q; Lexchin J; Yang L
BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37463786
[TBL] [Abstract][Full Text] [Related]
20. What Factors Hindered the Access to Essential Anticancer Medicine in Public Hospitals for the Local Population in Hubei Province, China.
Chen C; Feng Z; Ding Y; Yan Z; Wang J; Wang R; Feng D
Front Pharmacol; 2021; 12():734637. PubMed ID: 34630110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
